Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0909
Source ID: NCT00646035
Associated Drug: Paricalcitol Capsules
Title: A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: End Stage Renal Disease
Interventions: DRUG: paricalcitol capsules
Outcome Measures: Primary: The achievement of two consecutive greater than or equal to 30% decreases from baseline iPTH levels., 12 weeks|The incidence of clinically meaningful hypercalcemia and elevated Ca x P., 12 weeks |
Sponsor/Collaborators: Sponsor: Abbott
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 75
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2002-01
Completion Date:
Results First Posted:
Last Update Posted: 2008-03-28
Locations: Los Angeles, California, 90095, United States|Denver, Colorado, 80230, United States|Washington, District of Columbia, 20007, United States|Fort Myers, Florida, 33919, United States|Tampa, Florida, 33603, United States|Savannah, Georgia, 31405, United States|Evanston, Illinois, 60201, United States|Maywood, Illinois, 60153, United States|Indianapolis, Indiana, 46202, United States|New Orleans, Louisiana, 70112, United States|St. Louis, Missouri, 63110, United States|Las Vegas, Nevada, 89102, United States|Mineola, New York, 11501, United States|Cincinnati, Ohio, 45206, United States|Cincinnati, Ohio, 45220, United States|Cleveland, Ohio, 44195, United States|Portland, Oregon, 97210, United States|Charleston, South Carolina, 29425, United States|Memphis, Tennessee, 38105, United States|Nashville, Tennessee, 37205, United States|Houston, Texas, 77030, United States|Lubbock, Texas, 79430, United States|Krakow, 30-501, Poland|Krakow, Poland
URL: https://clinicaltrials.gov/show/NCT00646035